| FIELD OF APPLICATION | DETAILS |
|---|---|
| Generic Name | Tubocurarine |
| Active Ingredient | Tubocurarine chloride pentahydrate |
| US Brand Names | Tubocurarine Chloride |
| Drug Category | General Medicine |
| Drug Class | Prophylactic / preventive therapy, Palliative treatment, Immunosuppressive therapy, Targeted therapy |
| Route of Administration | Intravenous, Intramuscular |
| FDA Approval Status | FDA Approved (December 1951); Withdrawn (June 2008) Approved |
Tubocurarine: Overview
Tubocurarine is a naturally occurring plant-derived alkaloid that serves as the prototype non-depolarizing neuromuscular blocking agent. Historically extracted from South American curare plants, it was utilized in surgery to induce skeletal muscle paralysis and facilitate mechanical ventilation.
What Is Tubocurarine & How Does It Work?
Tubocurarine acts as a non-depolarizing neuromuscular blocker by inhibiting acetylcholine activity at the neuromuscular junction. At the cellular level, it acts as a reversible competitive antagonist at postsynaptic nicotinic acetylcholine receptors, specifically targeting the neuronal acetylcholine receptor subunit alpha-2. By repeatedly associating and dissociating from these receptor sites without activating them, Tubocurarine prevents endogenous acetylcholine from binding. This block prevents muscle membrane depolarization, halting action potential propagation and producing flaccid paralysis of skeletal muscles, beginning with small eye and facial muscles and progressing to the trunk and diaphragm.
Is Tubocurarine FDA Approved?
Tubocurarine received initial prescription approval from the United States Food and Drug Administration in December 1951 as an injectable neuromuscular blocker. The brand-name drug products were voluntarily withdrawn from the US market in June 2008 as modern agents with faster onset and cleaner side-effect profiles replaced it. In historical General Medicine and surgical anesthesia settings, anesthesiologists utilized Tubocurarine to maintain abdominal muscle relaxation and facilitate endotracheal intubation.
What Is Tubocurarine Used For?
- Historical induction of skeletal muscle relaxation during major abdominal and thoracic surgical procedures under general anesthesia.
- Facilitation of endotracheal intubation and control of mechanical ventilation in surgical and intensive care settings.
- Historical reduction of muscle contraction intensity during electroconvulsive therapy (ECT) and management of tetanus spasms.
Before Taking Tubocurarine: Contraindications & Precautions
Because Tubocurarine causes total respiratory muscle paralysis, significant histamine release, and autonomic ganglion blockade, strict clinical screening was required before its use.
Who Should Not Take Tubocurarine?
Tubocurarine is strictly contraindicated in patients with known hypersensitivity to tubocurarine chloride, curare alkaloids, or diarylethers. It must never be administered to patients without an established artificial airway and full mechanical ventilation support. Patients with severe allergic asthma, severe cardiovascular instability, or known history of severe hypotension should avoid Tubocurarine due to its strong histamine-releasing and ganglion-blocking properties.
Tubocurarine: Pregnancy & Fertility
Clinical safety data regarding Tubocurarine during pregnancy demonstrate that it crosses the placental barrier in minimal quantities due to its highly ionized quaternary ammonium structure. Historically, it was used cautiously during cesarean sections without causing direct fetal paralysis at standard surgical doses. Studies assessing the direct impact of Tubocurarine on human fertility demonstrate no conclusive evidence of permanent reproductive toxicity.
Tell Your Doctor Before Taking Tubocurarine
Inform your anesthesiologist if you have a history of myasthenia gravis, myasthenic syndrome, or other chronic neuromuscular disorders. Disclose any existing severe kidney disease, liver dysfunction, cardiac arrhythmias, or low blood pressure. List all current prescription medications, aminoglycoside antibiotics, and anesthetics being administered.
Tubocurarine: Dosage & Administration
Tubocurarine was formulated as a sterile 3 mg/mL liquid solution intended exclusively for intravenous or intramuscular injection by trained anesthesia professionals.
- Intravenous Solution (3 mg/mL): Administered as a slow intravenous injection over 60 to 90 seconds.
- Neuromuscular Monitoring: Administered using peripheral nerve stimulation to evaluate muscle twitch suppression and paralysis depth.
- Pharmacological Reversal: Reversed at the end of surgery using anticholinesterase agents like neostigmine combined with atropine.
Standard Tubocurarine Dosing
In historical adult surgical anesthesia, the initial intravenous paralytic dose of Tubocurarine ranged from 0.16 mg/kg to 0.5 mg/kg (typically 6 mg to 9 mg) injected slowly over 60 to 90 seconds. Muscle relaxation onset occurred within 3 to 5 minutes, with a duration of action lasting 30 to 60 minutes. Supplementary doses of 3 mg to 4.5 mg were administered as needed for prolonged operations based on nerve stimulator response.
How Tubocurarine Is Administered
Tubocurarine was injected directly into a running intravenous line by an anesthesiologist. Continuous monitoring of muscle twitch responses using a peripheral nerve stimulator was required to tailor dosing and prevent prolonged post-operative paralysis.
Tubocurarine: Clinical Efficacy & Research
Established clinical consensus confirms that Tubocurarine was a landmark medical discovery that revolutionized modern surgical anesthesia by enabling complete abdominal muscle relaxation without deep toxic levels of general anesthetics. Clinical trials demonstrated that a single bolus provided reliable, long-acting non-depolarizing blockade lasting up to an hour. However, research highlighted significant clinical drawbacks, including pronounced systemic histamine release leading to bronchospasm, autonomic ganglion blockade causing severe hypotension, and a long duration of action, leading to its clinical replacement by modern agents like rocuronium, vecuronium, and cisatracurium.
Tubocurarine: Side Effects & Safety Profile
This medication does not have an FDA Black Box Warning. Although Tubocurarine lacked a formal modern boxed warning prior to its US withdrawal, official prescribing guidelines emphasized that it must be administered exclusively by personnel trained in general anesthesia, airway management, and mechanical ventilation.
Tubocurarine carries significant safety risks related to complete respiratory paralysis, autonomic ganglion blockade, and massive histamine release.
Common Tubocurarine Side Effects
- Transient skin flushing, erythema, or localized hives from histamine release
- Mild to moderate blood pressure drops (hypotension)
- Mild heart rate changes, including transient bradycardia or sinus tachycardia
- Excessive bronchial secretions, tearing, and mild salivation
Serious Tubocurarine Adverse Events
- Severe, prolonged respiratory paralysis and post-operative apnea requiring extended mechanical ventilation
- Severe bronchospasm and acute anaphylactoid reactions driven by massive histamine release
- Profound hypotension and circulatory collapse secondary to autonomic ganglion blockade
- Severe, exaggerated muscle weakness in patients with underlying myasthenia gravis or electrolyte imbalances
Managing Tubocurarine Side Effects
If prolonged neuromuscular blockade occurs, mechanical ventilation must be maintained continuously while administering intravenous anticholinesterase agents like neostigmine paired with atropine. If severe hypotension or bronchospasm develops, intravenous fluids, vasopressors, antihistamines, and bronchodilators should be administered immediately.
Tubocurarine: Interactions & What to Avoid
Combining Tubocurarine with drugs that impair neuromuscular transmission or lower blood pressure significantly enhances its toxicity risks.
Tubocurarine: Interactions
- Inhalational anesthetics (halothane, isoflurane, enflurane): Profoundly potentiate the depth and duration of Tubocurarine neuromuscular blockade.
- Aminoglycoside antibiotics (gentamicin, tobramycin, neomycin): Enhance neuromuscular inhibition, increasing the risk of prolonged respiratory failure.
- Electrolyte imbalances (hypokalemia, hypocalcemia, hypermagnesemia): Significantly enhance non-depolarizing muscle relaxation and delay spontaneous recovery.
Tubocurarine: Food & Alcohol
Dietary intake does not directly alter intravenous Tubocurarine, though standard pre-surgical fasting guidelines must be strictly enforced. Alcohol consumption enhances central nervous system depression and can alter cardiovascular stability during anesthesia.
Tubocurarine: Missed Dose, Overdose & Storage
Because Tubocurarine was administered exclusively during controlled surgical procedures, home self-administration guidelines do not apply.
Missed Dose of Tubocurarine
Missed dose scenarios do not occur, as Tubocurarine was administered on-demand as a single procedure-specific injection by healthcare providers.
Tubocurarine: Overdose & Emergency
Tubocurarine overdose causes profound muscle paralysis, complete respiratory failure, and severe hypotension. Emergency management requires continuous mechanical ventilation, airway securing, intravenous vasopressors, and administration of reversal agents like neostigmine once partial spontaneous recovery begins.
How To Store Tubocurarine
Store Tubocurarine injection vials at controlled room temperature between 15°C and 30°C (59°F and 86°F). Keep containers protected from light and freezing, and restricted to authorized medical personnel.
Tubocurarine: Patient Management & Monitoring
Continuous electrophysiological and vital sign monitoring was mandatory whenever Tubocurarine was administered.
Tests Before Starting Tubocurarine
- Baseline evaluation of renal function and liver function panels to assess elimination pathways.
- Pre-anesthetic screening for underlying myopathies, myasthenia gravis, severe asthma, or history of allergies.
Monitoring During Tubocurarine Treatment
- Continuous peripheral nerve stimulation monitoring to evaluate twitch suppression and paralysis depth.
- Continuous monitoring of blood pressure, heart rate, electrocardiogram (ECG), and mechanical ventilatory parameters.
Tubocurarine: Do’s and Don’ts
- Do ensure complete mechanical ventilation support and resuscitation equipment are fully operational before administration.
- Do utilize a peripheral nerve stimulator to accurately monitor muscle relaxation and guide reversal.
- Don’t administer Tubocurarine without an established endotracheal airway in place.
- Don’t attempt rapid pharmacological reversal until initial spontaneous twitch recovery is demonstrated.
Frequently Asked Questions
What was Tubocurarine used for in surgery?
Tubocurarine was used as an anesthesia adjunct to paralyze skeletal muscles, facilitate insertion of a breathing tube, and allow abdominal surgery.
Is Tubocurarine approved by the FDA?
Tubocurarine was approved by the US FDA in December 1951, but the brand-name products were voluntarily withdrawn in June 2008.
How does Tubocurarine cause muscle paralysis?
Tubocurarine competitively blocks acetylcholine from binding to nicotinic receptors at the neuromuscular junction, preventing muscle contraction signals.
What plant does Tubocurarine come from?
Tubocurarine is an alkaloid originally isolated from South American curare plants, historically used on hunting arrow tips.
Why does Tubocurarine cause low blood pressure?
Tubocurarine triggers systemic histamine release and blocks autonomic ganglia, which relaxes blood vessels and lowers blood pressure.
How is Tubocurarine paralysis reversed?
Neuromuscular blockade from Tubocurarine is reversed using anticholinesterase drugs like neostigmine combined with atropine.
Why was Tubocurarine replaced by modern muscle relaxants?
It was replaced because newer muscle relaxants work faster, wear off more predictably, and do not cause severe histamine release or hypotension.
References
- United States Food and Drug Administration. Tubocurarine Chloride Injection Historical Approval and Discontinuation Records.
- DrugBank Online Database. Tubocurarine Compound Summary (Accession Number DB01199).
- World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index: M03AA02 (Tubocurarine).
Legal Disclaimer
The information provided is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider at any hospital or any local clinic before starting or stopping any medication.
